Diabetes Treatment With Glucobay in Combination With Sulfonylurea

Bayer

Status: Completed

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Acarbose (Precose/Glucobay, BAYG5421)

Study type: Observational

Funder types: Industry

Identifiers

NCT01613105

GB0712IN (Other Identifier)

13927

Details and patient eligibility

About

In this prospective, non interventional, observational Post Marketing Survelliance study data are obtained on the efficacy, safety and tolerability of Glucobay treatment on top of sulfonylurea under daily life treatment conditions.Specifically investigated is the influence of Glucobay on Post Prandial Blood Glucose and HbA1c as well as on pateint's weight when added to an already existing sulfonylurea therapy.The study is planned to carried out in 25000 - 30000 patients from 200 trial sites in India.The Post Marketing Survelliance study will be performed with commercially available medication prescribed within regular practice of the physician. No other examination will be performed than would be done without Post Marketing Survelliance study.

Enrollment: 4,564 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patient with type 2 diabetes with one of the following treatment ongoing : 1) Sulfonylurea 2) Sulfonylurea + OHA. In such patients, if investigator feels that addition of acarbose would be benficial for the patients

Exclusion criteria

• According to local product information

Trial design

4,564 participants in 1 patient group

Group 1

Treatment:

Drug: Acarbose (Precose/Glucobay, BAYG5421)